NO20055417L - Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor - Google Patents

Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Info

Publication number
NO20055417L
NO20055417L NO20055417A NO20055417A NO20055417L NO 20055417 L NO20055417 L NO 20055417L NO 20055417 A NO20055417 A NO 20055417A NO 20055417 A NO20055417 A NO 20055417A NO 20055417 L NO20055417 L NO 20055417L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
composition containing
histone deacetylase
deacetylase inhibitor
containing histone
Prior art date
Application number
NO20055417A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055417D0 (no
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20055417D0 publication Critical patent/NO20055417D0/no
Publication of NO20055417L publication Critical patent/NO20055417L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055417A 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor NO20055417L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
NO20055417D0 NO20055417D0 (no) 2005-11-16
NO20055417L true NO20055417L (no) 2005-12-19

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055417A NO20055417L (no) 2003-05-26 2005-11-16 Farmasoytisk blanding inneholdene histon-deacetylaseinhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (enExample)
EP (1) EP1626719A1 (enExample)
JP (1) JP2006526031A (enExample)
KR (1) KR100938712B1 (enExample)
CN (2) CN101322707A (enExample)
AR (1) AR045318A1 (enExample)
AU (1) AU2004241873C1 (enExample)
BR (1) BRPI0410959A (enExample)
CA (4) CA2634766A1 (enExample)
CL (1) CL2004001278A1 (enExample)
CO (1) CO5660262A2 (enExample)
CR (1) CR8163A (enExample)
CU (1) CU23490B7 (enExample)
EC (1) ECSP056253A (enExample)
IL (1) IL171941A0 (enExample)
ME (1) MEP32308A (enExample)
MX (1) MXPA05012345A (enExample)
NO (1) NO20055417L (enExample)
NZ (1) NZ543591A (enExample)
PE (1) PE20050206A1 (enExample)
RS (1) RS20050884A (enExample)
RU (1) RU2322971C2 (enExample)
TW (1) TW200505424A (enExample)
UA (1) UA81499C2 (enExample)
UY (1) UY28330A1 (enExample)
WO (1) WO2004103369A1 (enExample)
ZA (1) ZA200509515B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339631B1 (no) * 2004-10-08 2017-01-16 Indena Spa Semisynteseprosess for fremstillingen av 10-deacetyl-N-debenzoyl-paklitaxel.

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
KR20080003334A (ko) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
JP5409015B2 (ja) 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
SI2350005T1 (sl) * 2008-08-29 2012-03-30 Bayer Pharma AG Polimorf B N aminofenil N piridin il metoksikarbonilaminometil benzamida MS
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
EP2395972A4 (en) * 2009-02-11 2014-02-12 Liangping Yu PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
EP2424516A4 (en) * 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
JP2013503174A (ja) * 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
IN2014CN02501A (enExample) * 2011-09-30 2015-06-26 Vertex Pharma
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
EA201790604A1 (ru) 2014-09-17 2017-09-29 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
NZ518668A (en) * 1999-11-10 2004-04-30 Warner Lambert Co Combination chemotherapy comprising acetyldinaline and paclitaxal and/or carboplatin
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO339631B1 (no) * 2004-10-08 2017-01-16 Indena Spa Semisynteseprosess for fremstillingen av 10-deacetyl-N-debenzoyl-paklitaxel.

Also Published As

Publication number Publication date
ZA200509515B (en) 2006-07-26
RU2005140570A (ru) 2006-06-10
RU2322971C2 (ru) 2008-04-27
AU2004241873C1 (en) 2009-01-22
BRPI0410959A (pt) 2006-07-04
US20070098816A1 (en) 2007-05-03
MXPA05012345A (es) 2006-02-08
MEP32308A (en) 2010-10-10
ECSP056253A (es) 2006-10-25
NZ543591A (en) 2009-09-25
CU23490B7 (es) 2010-02-23
AR045318A1 (es) 2005-10-26
PE20050206A1 (es) 2005-03-26
NO20055417D0 (no) 2005-11-16
CA2634765A1 (en) 2004-12-02
CA2527191A1 (en) 2004-12-02
RS20050884A (sr) 2008-04-04
IL171941A0 (en) 2006-04-10
AU2004241873B2 (en) 2008-05-08
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
KR100938712B1 (ko) 2010-01-25
AU2004241873A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
CA2634709A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
AU2004241873B8 (en) 2008-05-29
TW200505424A (en) 2005-02-16
KR20060009371A (ko) 2006-01-31
WO2004103369A1 (en) 2004-12-02
UA81499C2 (en) 2008-01-10
CN1794991A (zh) 2006-06-28
CL2004001278A1 (es) 2005-05-06
UY28330A1 (es) 2004-12-31
JP2006526031A (ja) 2006-11-16
EP1626719A1 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
UA81499C2 (en) Pharmaceutical composition containing histone deacetylase inhibitor
MXPA06000013A (es) Agente terapeutico para sarcoma de tejido suave.
EA202191361A1 (ru) Способы лечения муковисцидоза
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
EP4208461A4 (en) NOVEL COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
NO20054681L (no) Farmasoytiske produkter
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20054072L (no) Terapeutisk middel for ryggmargsskade omfattende interleukin-6 antagonist.
DK3976604T3 (da) 1,3,4-oxadiazol-derivatforbindelser som histondeacetylase 6-hæmmer og den farmaceutiske sammensætning, der omfatter den samme
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
HUE068516T2 (hu) 1,3,4-Oxadiazol-származék vegyületek mint hiszton-deacetiláz-6 inhibitorok és ilyen vegyületeket tartalmazó gyógyászati kompozíció
EP4288419A4 (en) 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
EP4110780A4 (en) 1,3,4OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONEDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREOF
CA3247655A1 (en) HISTONE DEACETYLASE 6 (HDAC6) INHIBITION
FR2867682B1 (fr) Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
DE602004020488D1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
AP2007004188A0 (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
TW200638927A (en) Bambuterol and integrin inhibitor combination
EP1586307A3 (de) Kosmetische und dermatologische Zubereitungen mit konserviertem Taurin
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application